FERNANDO GALASSI STOCCO NETO
Projetos de Pesquisa
Unidades Organizacionais
Instituto do Câncer do Estado de São Paulo, Hospital das Clínicas, Faculdade de Medicina
SCPACEX-62, Hospital Universitário
SCPACEX-62, Hospital Universitário
9 resultados
Resultados de Busca
Agora exibindo 1 - 9 de 9
conferenceObject Rapid conversion of atrial fibrillation with pulmonary delivery of flecainide in large animal models(2018) VERRIER, Richard L.; STOCCO, Fernando G.; EVARISTO, Ederson; SCHULER, Carlos A.; RIO, Carlos del; RANGACHARI, Narsi; BELARDINELLI, Luiz- Accelerated conversion of atrial fibrillation to normal sinus rhythm by pulmonary delivery of flecainide acetate in a porcine model(2018) VERRIER, Richard L.; BORTOLOTTO, Alexandre L.; SILVA, Bruna A.; MARUM, Alexandre A.; STOCCO, Fernando G.; EVARISTO, Ederson; ANTONIO, Victor Z. de; SILVA, Anderson C.; BELARDINELLI, LuizBACKGROUND Pulmonary delivery of antiarrhythmic agents has the potential to increase rapidly targeted drug concentrations in pulmonary veins and left atrium to terminate atrial fibrillation (AF). OBJECTIVE We evaluated the efficacy of flecainide administered via intratracheal instillation in terminating AF in a reliable preclinical model. METHODS In 11 closed-chest anesthetized Yorkshire pigs, AF was induced by intrapericardial administration of acetylcholine (1 mL of 102.5 mM solution) followed by burst pacing and allowed to continue for 2 minutes before intratracheal flecainide (0.4 or 0.75 mg/kg) administration. RESULTS Both the 0.4-and 0.75-mg/kg doses of intratracheal flecainide significantly reduced AF duration by 35% (P = .02) and 54% (P = .001), respectively, compared to no-drug baseline. There was a strong inverse correlation (r(2) = 0.87; P = .03) between the duration of AF and the change in atrial depolarization duration in response to intratracheal flecainide. Induction of AF resulted in a marked increase in ventricular rate and corresponding reduction in mean arterial pressure, which returned to baseline levels within 5 minutes after conversion. CONCLUSION Intratracheal flecainide instillation is effective in rapidly converting AF to normal sinus rhythm and restoring mean arterial pressure and heart rate to baseline values. The basis for this efficacy is likely rapid absorption of the drug through the lungs and delivery as a first-pass bolus to the left atrial and ventricular chambers and then to the coronary arterial circulation. The antiAF effect of flecainide is inversely correlated with the drug's prolongation of atrial depolarization, implicating slowing of intra-atrial conduction as an important mechanism underlying conversion of AF to normal sinus rhythm.
- Comparative Pharmacokinetic and Electrocardiographic Effects of Intratracheal and Intravenous Administration of Flecainide in Anesthetized Pigs(2018) STOCCO, Fernando G.; EVARISTO, Ederson; SILVA, Anderson C.; ANTONIO, Victor Zandona de; PFEIFFER, Juergen; RANGACHARI, Narasimhan; BELARDINELLI, Luiz; VERRIER, Richard L.We compared the pharmacokinetic (PK) profile and electrocardiographic (ECG) changes in response to intratracheal instillation of flecainide acetate into the left atrium and ventricle with intravenous (IV) flecainide acetate administration. In 12 closed-chest anesthetized Yorkshire pigs, we monitored the QRS complex and PR, JT(c), and QT(c) intervals during sinus rhythm and correlated changes with venous plasma drug concentrations before and at 2, 5, 10, 15, and 30 minutes after drug administration. Intratracheal instillation of flecainide (0.75 and 1.5 mg/kg, rapid bolus) caused dose/concentration-dependent increases in the QRS complex duration of 10% and 19%, respectively, at 2 minutes, coinciding with peak venous plasma levels (1688 +/- 177 and 2808 +/- 217 ng/mL, respectively). IV infusion of flecainide (2 mg/kg) over 2 or 10 minutes similarly prolonged QRS complexes and PR intervals (both, P < 0.001). Intratracheal flecainide instillation increased PR interval briefly at 5 minutes. Neither intratracheal nor IV flecainide affected JT(c) or QT(c) intervals. Thus, the PK pattern of intratracheal instillation of flecainide is comparable to IV administration, although the absolute plasma concentrations were higher with IV infusion. Both modes of delivery elicited ECG changes that were consistent with the expected pharmacological activity of flecainide.
- Ranolazine reduces repolarization heterogeneity insymptomatic patients with diabetes and non-flow-limiting coronary artery stenosis(2018) EVARISTO, Ederson; STOCCO, Fernando G.; SHAH, Nishant R.; CHEEZUM, Michael K.; HAINER, Jon; FOSTER, Courtney; NEARING, Bruce D.; CARLI, Marcelo Di; VERRIER, Richard L.BackgroundExperimental evidence suggests that ranolazine decreases susceptibility to ischemia-induced arrhythmias independent of effects on coronary artery blood flow. ObjectiveIn symptomatic diabetic patients with non-flow-limiting coronary artery stenosis with diffuse atherosclerosis and/or microvascular dysfunction, we explored whether ranolazine reduces T-wave heterogeneity (TWH), an electrocardiographic (ECG) marker of arrhythmogenic repolarization abnormalities shown to predict sudden cardiac death. MethodsWe studied all 16 patients with analyzable ECG recordings during rest and exercise tolerance testing before and after 4weeks of ranolazine in the double-blind, crossover, placebo-controlled RAND-CFR trial (NCT01754259). TWH was quantified without knowledge of treatment assignment by second central moment analysis, which assesses the interlead splay of T waves in precordial leads about a mean waveform. Myocardial blood flow (MBF) was measured by positron emission tomography. ResultsAt baseline, prior to randomization, TWH during rest was 547V and was not altered following placebo (47 +/- 6V, p=.47) but was reduced by 28% (to 39 +/- 5V, p=.002) after ranolazine. Ranolazine did not increase MBF at rest. Exercise increased TWH after placebo by 49% (to 70 +/- 8V, p=.03). Ranolazine did not reduce TWH during exercise (to 75 +/- 16V), and there were no differences among the groups (p=.95, ANOVA). TWH was not correlated with MBF at rest before (r(2)=.07, p=.36) or after ranolazine (r(2)=.23, p=.06). ConclusionsIn symptomatic diabetic patients with non-flow-limiting coronary artery stenosis with diffuse atherosclerosis and/or microvascular dysfunction, ranolazine reduced TWH at rest but not during exercise. Reduction in repolarization abnormalities appears to be independent of alterations in MBF.
- EXERCISE AND PHARMACOLOGIC STRESS-INDUCED T-WAVE HETEROGENEITY FOR DETECTION OF CLINICALLY SIGNIFICANT CORONARY ARTERY STENOSIS(2018) SILVA, Anderson Carlos; ANTONIO, Victor Zandona De; SROUBEK, Jakub; GERVINO, Ernest; HO, Kalon; STOCCO, Fernando G.; NEARING, Bruce D.; VERRIER, Richard L.
- Exercise and pharmacologic stress-induced interlead T-wave heterogeneity analysis to detect clinically significant coronary artery stenosis(2020) SILVA, Anderson C.; ANTONIO, Victor Z. de; SROUBEK, Jakub; GERVINO, Ernest; HO, Kalon; MEDEIROS, Sofia A.; SILVA, Fernanda Tessarolo; PEDREIRA, Giovanna C.; STOCCO, Fernando G.; NEARING, Bruce D.; VERRIER, Richard L.Background: Despite widespread use of ETT and vasodilator-stress with myocardial perfusion imaging (MPI) for noninvasive detection of flow-limiting coronary artery disease, there is continued need to improve diagnostic accuracy. We examinedwhether measurement of interlead T-wave heterogeneity (TWH) during exercise tolerance testing (ETT) or pharmacologic stress testing improves detection of stenoses in large epicardial coronary arteries. Methods: All 137 patients at our institution who underwent diagnostic coronary angiography within 0 to 5 days after ETT (N = 81) or dipyridamole IV infusion (N = 58) in 2016 were studied, including 2 patients with both tests. Cases (N= 93) had angiographically significant stenosis (>= 50% of left main or >= 70% of an epicardial coronary artery >= 2 mm in diameter); controls (N= 44) didnot. TWH, i.e., interlead splay of T waves, was determined by second central moment analysis from precordial leads by an investigator blinded to angiographic results. Results: At rest, TWH levels were similar for cases and controls. ETT and dipyridamole stress testing increased TWH by 69% (p < 0.0001) and 27% (p < 0.0001), respectively, in cases. In controls, TWH did not change. Areas under the ROC curves for TWH increase for any flow-limiting coronary artery stenosis were 0.737 (p < 0.0001) for ETT and 0.818 (p < 0.0001) for dipyridamole stress testing. By contrast, neither ST-segment changes during ETT (p = 0.12) nor MPI during dipyridamole stress testing (p= 0.60) discriminated cases fromcontrols. Conclusions: TWH measurement is a novel method that improves detection of angiographically confirmed flow-limiting stenoses in large epicardial coronary arteries during both ETT andMPI during pharmacologic stress testing with dipyridamole.
conferenceObject PULMONARY DELIVERY OF THE CLASS IC ANTIARRHYTHMIC AGENT FLECAINIDE EXERTS A PREDOMINANT EFFECT ON ATRIAL COMPARED TO VENTRICULAR DEPOLARIZATION DURATION REVEALED BY INTRACARDIAC RECORDINGS(2018) ANTONIO, Victor Zandona De; SILVA, Anderson; STOCCO, Fernando G.; RANGACHARI, Narsi; BELARDINELLI, Luiz; VERRIER, Richard; ISRAEL, Beth- Marked exercise-induced T-wave heterogeneity in symptomatic diabetic patients with nonflow-limiting coronaryartery stenosis(2018) STOCCO, Fernando G.; EVARISTO, Ederson; SHAH, Nishant R.; CHEEZUM, Michael K.; HAINER, Jon; FOSTER, Courtney; NEARING, Bruce D.; GERVINO, Ernest; VERRIER, Richard L.BackgroundT-wave heterogeneity (TWH) independently predicted cardiovascular mortality in Health Survey 2000 based on 12-lead ECGs recorded at rest. We investigated whether TWH is elevated during exercise tolerance testing (ETT) in symptomatic diabetic patients with nonflow-limiting coronary artery stenosis compared to control subjects without diabetes. MethodsCases were all patients (n=20) with analyzable ECG recordings during both rest and ETT who were enrolled in the Effects of Ranolazine on Coronary Flow Reserve (CFR) in Symptomatic Patients with Diabetes and Suspected or Known Coronary Artery Disease (RAND-CFR) study (NCT01754259); median CFR was 1.44; 80% of cases had CFR <2. Control subjects (n=9) were nondiabetic patients who had functional flow reserve (FFR) >0.8, a range not associated with inducible ischemia. TWH was analyzed from precordial leads V-4, V-5, and V-6 by second central moment analysis, which assesses the interlead splay of T-waves about a mean waveform. ResultsDuring exercise to similar rate-pressure products (p=.31), RAND-CFR patients exhibited a 49% increase in TWH during exercise (rest: 495V; exercise: 73 +/- 8V, p=.003). By comparison, in control subjects, TWH was not significantly altered (rest: 52 +/- 11V; ETT: 38 +/- 5V, p=.19). ETT-induced ST-segment depression >1mm (p=.11) and T-peak-T-end (p=.18) and QTc intervals (p=.80) failed to differentiate cases from controls. ConclusionsTWH is capable of detecting latent repolarization abnormalities, which are present during ETT in diabetic patients with nonflow-limiting stenosis but not in control subjects. The technique developed in this study permits TWH analysis from archived ECGs and thereby enables mining of extensive databases for retrospective studies and hypothesis testing.
- Pulmonary delivery of flecainide causes a rate-dependent predominant effect on atrial compared with ventricular depolarization duration revealed by intracardiac recordings in an intact porcine model(2018) ANTONIO, Victor Z. de; SILVA, Anderson C.; STOCCO, Fernando G.; SILVA, Bruna A.; MARUM, Alexandre A.; BORTOLOTTO, Alexandre L.; BELARDINELLI, Luiz; VERRIER, Richard L.Background Pulmonary delivery of flecainide results in the rapid conversion of atrial fibrillation (AF) to normal sinus rhythm in large-animal models and is safe and well-tolerated by normal human volunteers. Objective Methods We investigated the effects of pulmonary delivery of flecainide on atrial and ventricular depolarization and repolarization duration. Intratracheal instillation (1.5 mg/kg, rapid push) of flecainide or sterile water (placebo) was performed in 12 closed-chest, anesthetized Yorkshire pigs with a catheter positioned at the bifurcation of the main bronchi. High-resolution electrograms obtained from catheters fluoroscopically positioned in the right atrium and left ventricle circumvented measurement errors due to the fusion of P and T waves in surface leads when rapid heart rates shortened the TP interval. Pacing was achieved using electrical stimuli delivered via right atrial catheter electrodes. Results Conclusion During sinus rhythm (98 +/- 4.7 beats/min), intratracheal flecainide caused comparable (P = 0.56) increases in atrial depolarization (P-a) duration by 22% (39.8 +/- 3.2 to 48.7 +/- 3.3 milliseconds) and left ventricular (LV) QRS complex duration by 20% (47.9 +/- 1.6 to 57.3 +/- 1.8 milliseconds) at peak effect at 2 minutes post-dosing. During right atrial pacing at 180 beats/min, P-a duration increased by 55% (37.0 +/- 2.0 to 57.2 +/- 1.6 milliseconds; P < 0.0001). The atrial response was greater (p = 0.001) than the 30% increase in LV QRS complex duration (46.6 +/- 1.7 to 60.6 +/- 2.5 milliseconds; P = 0.005). P-a duration and QRS complex duration were unchanged by placebo independent of pacing (P >= 0.4 for both). Atrial repolarization duration (PTa; P = 0.46) and QT(c) interval (P = 0.49) remained unchanged. Intratracheal flecainide exerts a rate-dependent, predominant effect on atrial compared with ventricular depolarization duration. Pulmonary delivery of flecainide could facilitate AF conversion to sinus rhythm with reduced ventricular proarrhythmia risk.